Torasemide | CAS#56211-40-6

Torasemide
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318892

CAS#: 56211-40-6

Description: Torasemide is a pyridine-sulfonyl urea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension.

Chemical Structure

Torasemide

CAS# 56211-40-6

Instruction

Theoretical Analysis

MedKoo Cat#: 318892
Name: Torasemide
CAS#: 56211-40-6
Chemical Formula: C16H20N4O3S
Exact Mass: 348.13
Molecular Weight: 348.420
Elemental Analysis: C, 55.16; H, 5.79; N, 16.08; O, 13.78; S, 9.20

Price and Availability

Size	Price	Availability	Quantity
1kg	USD -1
2g	USD 150
5g	USD 250
10g	USD 450
20g	USD 850
50g	USD 1450
100g	USD 2450
200g	USD 3850
500g	USD 5850
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Torasemide, Torsemide, Demadex, Diuver, Examide, Luprac

IUPAC/Chemical Name: 1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea

InChi Key: NGBFQHCMQULJNZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

SMILES Code: O=C(NC(C)C)NS(=O)(C1=C(NC2=CC=CC(C)=C2)C=CN=C1)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 348.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Kobalava ZhD, Kiiakbaev GK. [Ways of optimizing diuretic therapy in congestive heart failure, chronic place torasemide prolonged release]. Kardiologiia. 2014;54(4):69-77. Review. Russian. PubMed PMID: 25177788.

2: Evdokimova AG, Kovalenko EV, Evdokimov VV, Lozhkina MV. [Possibilities of the use of torasemide in clinical practice]. Kardiologiia. 2012;52(12):84-9. Review. Russian. PubMed PMID: 23237447.

3: Preobrazhenskiĭ DV, Nekrasova NI, Khoseva EN, Arystanova A, Talyzina IV, Pataraia SA. [Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension]. Kardiologiia. 2011;51(4):67-73. Review. Russian. PubMed PMID: 21623723.

4: Acuña C. [Update: prolonged-release torasemide]. Drugs Today (Barc). 2010 Jul;46 Suppl E:1-15. Review. Spanish. PubMed PMID: 20882198.

5: Lyseng-Williamson KA. Torasemide prolonged release. Drugs. 2009 Jul 9;69(10):1363-72. doi: 10.2165/00003495-200969100-00006. Review. PubMed PMID: 19583454.

6: Ishido H, Senzaki H. Torasemide for the treatment of heart failure. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):127-32. Review. PubMed PMID: 18537599.

7: Preobrazhenskiĭ DV, Sidorenko BA, Tarykina EV, Batyraliev TA, Marenich AV. [Torasemide--new generation loop diuretic: clinical pharmacology and therapeutic application]. Kardiologiia. 2006;46(10):75-86. Review. Russian. PubMed PMID: 17159856.

8: Moiseev SV. [Clinical efficacy and safety of administration of loop diuretic torasemide]. Kardiologiia. 2006;46(4):71-4. Review. Russian. PubMed PMID: 16710209.

9: Kido H, Ohtaki Y. [Torasemide (LUPRAC): a review of its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi. 2001 Aug;118(2):97-105. Review. Japanese. PubMed PMID: 11530685.

10: Knauf H, Mutschler E. Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998 Jan;34(1):1-24. Review. PubMed PMID: 9474471.

11: Brater DC. Benefits and risks of torasemide in congestive heart failure and essential hypertension. Drug Saf. 1996 Feb;14(2):104-20. Review. PubMed PMID: 8852525.

12: Fiaccadori F, Pasetti GC, Pedretti G, Pizzaferri P, Elia GF. Comparative analysis of torasemide and furosemide in liver cirrhosis. Cardiology. 1994;84 Suppl 2:80-6. Review. PubMed PMID: 7954549.

13: Baumgart P. Torasemide in comparison with thiazides in the treatment of hypertension. Cardiovasc Drugs Ther. 1993 Jan;7 Suppl 1:63-8. Review. PubMed PMID: 8435378.

14: Brater DC. Pharmacokinetics and pharmacodynamics of torasemide in health and disease. J Cardiovasc Pharmacol. 1993;22 Suppl 3:S24-31. Review. PubMed PMID: 7506334.

15: Achhammer I, Metz P. Low dose loop diuretics in essential hypertension. Experience with torasemide. Drugs. 1991;41 Suppl 3:80-91. Review. PubMed PMID: 1712717.

16: Knauf H, Spahn H, Mutschler E. The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. Drugs. 1991;41 Suppl 3:23-34. Review. PubMed PMID: 1712713.

17: López B, González A, Hermida N, Laviades C, Díez J. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl. 2008 Dec;(111):S19-23. doi: 10.1038/ki.2008.512. Review. PubMed PMID: 19034320.

18: Grajewska M, Sulikowska B, Manitius J. [Torasemide (Trifas) in clinical practice--own experience]. Przegl Lek. 2003;60(1):24-6. Review. Polish. PubMed PMID: 12884642.

19: Escolar M, Quetglas EG, Honorato J. [Torasemide]. Rev Med Univ Navarra. 1996 Oct-Dec;40(4):45-52. Review. Spanish. PubMed PMID: 9499834.

20: Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. Review. PubMed PMID: 7705212.

Your view history

Torasemide featured